/

Sociétés

As

Non vérifié

AstraZeneca

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

87 communiqués de presse

Voir tous les communiqués de presse

04/12/2025

Événements

Biotechnologie

Santé Publique

Industrie pharmaceutique

Santé

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Source

Émetteur

1.00

0

02/12/2025

Science

Cardiologie

Biotechnologie

Industrie pharmaceutique

Santé Publique

Santé

Hygiène alimentaire

Industrie

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Source

Émetteur

1.00

0

26/11/2025

Événements

Industrie

Oncologie

Santé

Hygiène alimentaire

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Source

Émetteur

1.00

0

21/11/2025

Industrie

Biotechnologie

Industrie pharmaceutique

Santé

Médecine - Divers

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Source

Émetteur

1.00

0

09/11/2025

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Source

Émetteur

1.00

0

07/11/2025

Événements

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Source

Émetteur

1.00

0

06/11/2025

Biotechnologie

Industrie pharmaceutique

Santé

Marché financier

AstraZeneca's 9M and Q3 2025 Financial Results

Source

Émetteur

1.00

0

19/10/2025

Oncologie

Santé

Hygiène alimentaire

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Événements

Industrie

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

Source

Émetteur

1.00

0

18/10/2025

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

Événements

Industrie

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

Source

Émetteur

1.00

0

17/10/2025

Multimédia

Biotechnologie

Hygiène alimentaire

Santé

Vitrines/Shopping

Santé Publique

Industrie pharmaceutique

Science

Jeunesse

Médecine - Divers

Industrie

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0